Advertisement

Towards the future of upper tract urothelial carcinoma surveillance: lessons learnt from bladder cancer urinary biomarkers

  • Andrea Gallioli
  • Romain Boissier
  • Angelo Territo
  • Alberto Breda
Letter to Editor

Notes

Author contributions

Gallioli: project development, data collection, and manuscript writing/editing. Boissier: data analysis and manuscript editing. Territo: data collection and management. Breda: project development and manuscript editing.

Funding

None.

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

After ethical committee approval, all patients enrolled in our study signed an informed consent.

Conflict of interest

All the authors declare that they have no potential conflicts of interest.

References

  1. 1.
    Maas M, Bedke J, Stenzl A, Todenhöfer T (2018) Can urinary biomarkers replace cystoscopy? World J Urol.  https://doi.org/10.1007/s00345-018-2505-2 (Epub ahead of print) CrossRefPubMedGoogle Scholar
  2. 2.
    Soria F, Droller MJ, Lotan Y et al (2018) An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol 36:1981–1995.  https://doi.org/10.1007/s00345-018-2380-x CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Faiena I, Rosser CJ, Chamie K et al (2018) Diagnostic biomarkers in non-muscle invasive bladder cancer. World J Urol.  https://doi.org/10.1007/s00345-018-2567-1 (Epub ahead of print) CrossRefPubMedGoogle Scholar
  4. 4.
    Lotan Y, Shariat SF, Schmitz-Drager BJ et al (2010) Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 28:441–448.  https://doi.org/10.1016/j.urolonc.2009.11.004 CrossRefPubMedGoogle Scholar
  5. 5.
    Witjes JA, Morote J, Cornel EB et al (2018) Performance of the Bladder EpiCheck™ Methylation Test for patients under surveillance for non–muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Onc 1:307–313.  https://doi.org/10.1016/j.euo.2018.06.011 CrossRefGoogle Scholar
  6. 6.
    Messer J, Shariat SF, Brien JC et al (2011) Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701–705.  https://doi.org/10.1111/j.1464-410X.2010.09899.x CrossRefPubMedGoogle Scholar
  7. 7.
    Monteiro-Reis S, Leça L, Mafalda A et al (2014) Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer 50:226–233.  https://doi.org/10.1016/j.ejca.2013.08.025 CrossRefPubMedGoogle Scholar
  8. 8.
    Run-Qi G, Gen-Yan X, Kai-Wei Y et al (2018) Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: a prospective, single-center study. Urol Oncol 36(7):342.e15–342.e23.  https://doi.org/10.1016/j.urolonc.2018.04.001 CrossRefGoogle Scholar
  9. 9.
    Bensalah K, Montorsi F, Shariat SF (2007) Challenges of cancer biomarker profiling. Eur Urol 52:1601–1609.  https://doi.org/10.1016/j.eururo.2007.09.036 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Fundació Puigvert, Department of UrologyAutonomous University of BarcelonaBarcelonaSpain
  2. 2.Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community HealthUniversity of MilanMilanItaly
  3. 3.Department of UrologyAix-Marseille University, APHM, La Conception Academic HospitalMarseilleFrance

Personalised recommendations